Bladder Cancer. Malignant neoplasm of bladder
Conditions
Interventions
Intervention 1: Intervention group: A group of randomly selected patients received an intravesical injection of Bacillus-Calmette-Guerin (BCG) every week for up to 6 weeks and then a monthly intravesi
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with non-muscle invasive bladder cancer (stage Ta and T1). Have a history of transurethral resection of tumor (TURT) one month before Bacillus-calmette-guerin (BCG) therapy. Have no previous history of BCG instillation. Do not have contraindications to BCG instillation.
Exclusion criteria
Exclusion criteria: Patients with muscle invasive bladder cancer Have a history of transurethral resection of tumor (TURT) more than one month before Bacillus-calmette-guerin (BCG) therapy. Have previous history of BCG instillation. Have contraindications to BCG instillation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acceptance rate by patients. Timepoint: After induction dose and then every month for up to 6 months. Method of measurement: Visit and follow up the patients.;Complications. Timepoint: After induction dose and then every month for up to 6 months. Method of measurement: Patient symptoms and complaints. | — |
Secondary
| Measure | Time frame |
|---|---|
| Recurrence rate. Timepoint: Every 3 months to 2 years. Method of measurement: laboratory tests , cytology and cystoscopy.;Progress rate. Timepoint: Every 3 months to 2 years. Method of measurement: laboratory tests , cytology and cystoscopy. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNasser Shakhssalim
Shahid Beheshti University of Medical Sciences
Outcome results
None listed